STORM Therapeutics Ltd.
๐ฌ๐งUnited Kingdom
- Country
- ๐ฌ๐งUnited Kingdom
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
Phase 1
Recruiting
- Conditions
- Metastatic Non-small Cell Lung CancerMetastatic MelanomaMetastatic Endometrial CancerMetastatic Head-and-neck Squamous-cell CarcinomaSolid Tumor
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- STORM Therapeutics LTD
- Target Recruit Count
- 188
- Registration Number
- NCT06975293
- Locations
- ๐บ๐ธ
The START Center, San Antonio, Texas, United States
๐บ๐ธNEXT Oncology, Fairfax, Virginia, United States
Oral Administration of STC-15 in Subjects with Advanced Malignancies
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- STORM Therapeutics LTD
- Target Recruit Count
- 42
- Registration Number
- NCT05584111
- Locations
- ๐บ๐ธ
Honor Health, Scottsdale, Arizona, United States
๐บ๐ธThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธSouth Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath